CD8A and cancer: A proof of principle for WT1 epitope modification to enhance anti-WT1 CD8+ T-cell responses has been well established in HLA-A24+ cancer patients whereby the modified Y236M-variant of the HLA-A24/WT1235-243 (CYTWNQMNL) epitope has been used in a number of peptide vaccination clinical trials involving both adults and children with hematological and solid cancers in Japan,9, 10, 11, 12, 13 with some patients within each study having positive clinical outcomes associated with an increase in WT1-specific CD8+ T-cell responses.